Eli Lilly's 'game-changing' diabetes drug could boost the stock, SVB Securities says

The Eli Lilly logo is shown on one of the company's offices in San Diego, California, September 17, 2020.
Mike Blake | Reuters

Eli Lilly's new diabetes drug, which may also address obesity in patients, could lead to even more gains for the company's stock, according to SVB Securities.